Notice of Allowability	Application No.	Applicant(s)		
	09/806,525	MCKEOWN ET AL	MCKEOWN ET AL.	
	Examiner	Art Unit		
	Gary B. Nickol Ph.D.	1642		
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R	(OR REMAINS) CLOSED in or other appropriate commu IGHTS . This application is s	this application. If not including this application. If not include the thick in th	led course. THIS	
1. \boxtimes This communication is responsive to <u>06-16-04</u> .				
2. The allowed claim(s) is/are 2,10,11,14-16 and 18.			Í	
3. The drawings filed on are accepted by the Examine	r.			
 4. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" 	e been received. e been received in Application cuments have been received	n No d in this national stage applica		
noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	IENT of this application. itted. Note the attached EXA	MINER'S AMENDMENT or N		
		declaration is deficient.		
 CORRECTED DRAWINGS (as "replacement sheets") mus (a) ☐ including changes required by the Notice of Draftspers 		(DTO 049) attached		
	-	(FTO-940) attached		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date		in the Office action of		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t			e back) of	
7. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATE FOR THE DEPOSIT OF BIO	ERIAL must be submitted. PLOGICAL MATERIAL.	Note the	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. ☐ Notice of Inf	ormal Patent Application (PT	O-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)		 6. ☐ Interview Summary (PTO-413), Paper No./Mail Date 7. ☐ Examiner's Amendment/Comment 		
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date				
4. Examiner's Comment Regarding Requirement for Deposit		Statement of Reasons for Alle	owance	
of Biological Material	9.			
Jangenila GARY NICKOL PRIMARY EXAMIN		Gary B. Nickol Ph. Primary Examiner Art Unit: 1642	D.	

Application/Control Number: 09/806,525

Art Unit: 1642

Response to Amendment

The Amendment filed June 16, 2004 in response to the Final Office Action of February 13, 2004 is acknowledged and has been entered.

Claims 2, 10-11, 14-16, 18 are allowed.

Requirement for the Information/Deposit of Biological Material

The specification teaches (page 11, lines 5-6) that the <u>claimed</u> Ab4 antibody is available from Oncogene Science, Inc. as catalogue No. HCS16. The Office will accept commercial availability as evidence that a biological material is known and readily available **only** when the evidence is clear and convincing that the public has access to the material. However, the PTO could not establish whether or not the AB4 antibody was commercially available from Oncogene Science Inc.

MPEP 2404.1 states that in an application where the invention requires access to specific biological material, applicant could show that the biological material is accessible because it is known and readily available to the public. A material may be known in the sense that its existence has been published, but is not available to those who wish to obtain that particular known biological material. Likewise, a biological material may be available in the sense that those having possession of it would make it available upon request, but no one has been informed of its existence. The concepts of "known and readily available" are considered to reflect a level of public accessibility to a necessary component of an invention disclosure that is consistent with an ability to make and use the invention. To avoid the need for a deposit on this basis, the biological material must be **both known and readily available** - neither concept alone is sufficient. Thus, to obviate this situation, applicant must provide evidence that the Ab4 antibody is commercially available and that it is known and readily available to the public because without such assurance, one of ordinary skill in the art could not be assured of the ability to practice the invention as claimed.

Application/Control Number: 09/806,525

Art Unit: 1642

All other rejections and or objections are withdrawn in view of applicant's amendments

and arguments there to.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Gary B. Nickol Ph.D. whose telephone number is 571-272-0835.

The examiner can normally be reached on M-Th, 8:30-5:30; alternate Fri., 8:30-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gary B. Nickol Ph.D. Primary Examiner

Page 3

Art Unit 1642

June 28, 2004

GARY NICKOL PRIMARY EXAMINER

Mary & nikol